{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T08:04:09Z","timestamp":1784707449401,"version":"3.55.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008967","name":"Philipps-Universit\u00e4t Marburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008967","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00066-026-02556-7","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T12:10:29Z","timestamp":1781179829000},"page":"908-910","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dauer der Androgendeprivationstherapie bei der Radiotherapie des lokalisierten Prostatakarzinoms\u00a0\u2013 braucht es wirklich 36\u00a0Monate?","Duration of androgen deprivation therapy with radiotherapy for localized prostate cancer: is 36\u00a0months still necessary?"],"prefix":"10.1007","volume":"202","author":[{"given":"Niklas","family":"Recknagel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Heinzelbecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Adeberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"issue":"1","key":"2556_CR1","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1001\/jamaoncol.2025.4800","volume":"12","author":"NG Zaorsky","year":"2026","unstructured":"Zaorsky\u00a0NG et\u00a0al (2026) Optimal Duration of Androgen Deprivation Therapy With Definitive Radiotherapy for Localized Prostate Cancer: A Meta-Analysis. JAMA Oncology 12(1):58\u201365","journal-title":"JAMA Oncology"},{"key":"2556_CR2","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, D.K., AWMF) (2025) S3-Leitlinie Prostatakarzinom."},{"issue":"2","key":"2556_CR3","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"P Cornford","year":"2024","unstructured":"Cornford\u00a0P et\u00a0al (2024) EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer\u20142024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. European Urology 86(2):148\u2013163","journal-title":"European Urology"},{"key":"2556_CR4","unstructured":"National Comprehensive Cancer Network (2024) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Prostate Cancer."},{"issue":"5","key":"2556_CR5","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","volume":"67","author":"PL Nguyen","year":"2015","unstructured":"Nguyen\u00a0PL et\u00a0al (2015) Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol 67(5):825\u2013836","journal-title":"Eur Urol"},{"issue":"16_suppl","key":"2556_CR6","doi-asserted-by":"publisher","first-page":"12067","DOI":"10.1200\/JCO.2025.43.16_suppl.12067","volume":"43","author":"D Lazris","year":"2025","unstructured":"Lazris\u00a0D et\u00a0al (2025) Androgen deprivation therapy and quality of life: A\u00a0concept map analysis. Journal of Clinical Oncology 43(16_suppl):12067\u201312067","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"2556_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2022.101142","volume":"8","author":"BS Laughlin","year":"2023","unstructured":"Laughlin\u00a0BS et\u00a0al (2023) Initial Quality of Life and Toxicity Analysis of a Randomized Phase 3 Study of Moderately Hypofractionated Radiation Therapy With or Without Androgen Suppression for Intermediate-Risk Adenocarcinoma of the Prostate: PCG GU003. Adv Radiat Oncol 8(3):101142","journal-title":"Adv Radiat Oncol"},{"issue":"10231","key":"2556_CR8","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman\u00a0MS et\u00a0al (2020) Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 395(10231):1208\u20131216","journal-title":"Lancet"},{"key":"2556_CR9","doi-asserted-by":"publisher","first-page":"S676","DOI":"10.1016\/j.annonc.2021.08.1162","volume":"32","author":"BA Hadaschik","year":"2021","unstructured":"Hadaschik\u00a0BA et\u00a0al (2021) 649TiP PRIMORDIUM: A randomized, international, trial-in-progress of adding apalutamide to radiotherapy and an LHRH agonist in high-risk patients with PSMA-PET-positive hormone-sensitive prostate cancer. Annals of Oncology 32:S676\u2013S677","journal-title":"Annals of Oncology"},{"issue":"18","key":"2556_CR10","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1200\/JCO.2016.70.2811","volume":"35","author":"DE Spratt","year":"2017","unstructured":"Spratt\u00a0DE et\u00a0al (2017) Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease. J\u00a0Clin Oncol 35(18):1991\u20131998","journal-title":"J Clin Oncol"},{"key":"2556_CR11","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.euros.2022.06.004","volume":"42","author":"R Hogenhout","year":"2022","unstructured":"Hogenhout\u00a0R et\u00a0al (2022) Detailed Evaluation of Androgen Deprivation Overtreatment in Prostate Cancer Patients Compared to the European Association of Urology Guidelines Using Long-term Data from the European Randomised Study of Screening for Prostate Cancer Rotterdam. European Urology Open Science 42:42\u201349","journal-title":"European Urology Open Science"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-026-02556-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-026-02556-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-026-02556-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T07:54:54Z","timestamp":1784706894000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-026-02556-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":11,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2556"],"URL":"https:\/\/doi.org\/10.1007\/s00066-026-02556-7","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"assertion":[{"value":"18 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.\u00a0Recknagel, J.\u00a0Heinzelbecker und S.\u00a0Adeberg geben an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}